To approach our ultimate goal of a TIS-focused genetic predictor in lymphoma, we defined an in vitro-senescence signature based on genes being differentially expressed between ADR-senescent control;bcl2 vs. equally ADR-exposed Suv39h1−;bcl2 and, hence, senescence-incapable, or untreated Bcl2-infected lymphomas (Fig. 5a). The gene discussed is BCL2; the disease is lymphoma.